MDL Track
MDL 3180
Dupixent (dupilumab) cutaneous T-cell lymphoma
Pharmaceutical · claims alleging dupilumab (Dupixent) causes or accelerates cutaneous T-cell lymphoma (CTCL) and other lymphoproliferative disorders, centralized in MDL 3180
Defendant
Sanofi-Aventis U.S. LLC
MDL / Track
MDL 3180
D.N.J.
Judge
Judge Zahid N. Quraishi
Plaintiffs
26 pending
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Plaintiffs filed a motion for transfer with the JPML on February 13, 2026, seeking consolidation of all federal Dupixent lymphoma cases into MDL-3180 in the Northern District of Georgia. At least 15 cases are pending across 12 district courts, with four already filed in the Northern District of Georgia. The litigation alleges Sanofi and Regeneron failed to warn that the IL-4/IL-13 inhibitor causes, masks, or accelerates cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome. The FDA placed Dupixent on its Q4 2024 FAERS potential serious risks list for CTCL in March 2025 and confirmed it is evaluating the need for regulatory action.
Causation Theory
Plaintiffs advance dual causation theories: (1) dupilumab's IL-4Rα blockade upregulates IL-13RA2 signaling, altering T-cell microenvironment dynamics to directly cause or accelerate CTCL; and (2) the drug masks early CTCL symptoms that mimic eczema, delaying diagnosis until advanced stages. A 2024 Journal of the American Academy of Dermatology study reported a 4.1-fold increased CTCL risk in atopic dermatitis patients treated with dupilumab versus untreated patients, with median diagnosis exceeding one year post-initiation. A WHO VigiBase analysis reported a statistically significant odds ratio of 11.11 (95% CI 6.77–18.23) for CTCL reports with dupilumab compared to other biologics. A January 2026 Frontiers in Medicine large-scale retrospective cohort study found no statistically significant increased lymphoma risk, though plaintiffs distinguish this as suffering from selection bias by comparing against other systemic therapies rather than untreated controls.
Case Management Orders
Litigation status
JPML centralized federal Dupixent CTCL cases into MDL No. 3180 in the District of New Jersey on June 4, 2026, assigning Judge Zahid N. Quraishi to preside. The MDL currently holds 26 pending actions; litigation remains in early organizational stage with no bellwether trials scheduled.
MDL Track
MDL 3180
Dupixent (dupilumab) cutaneous T-cell lymphoma
Geographic exposure
Over 1 million patients treated with Dupixent since 2017 FDA approval; 200+ CTCL cases reported through 2024 per litigation. FDA identified CTCL as potential serious risk March 2025; evaluating label update, no recall issued. 15+ federal lawsuits pending across 12 district courts as of May 2026.
Michael Durkin v. Sanofi-Aventis U.S. LLC et al., filed Feb. 4, 2026, M.D. Fla. — CTCL (Mycosis Fungoides type) diagnosis Oct. 2025 after Dupixent treatment for eczema.
Michael Phillips v. Sanofi/Regeneron, filed Dec. 2025, E.D. La. — Dual CTCL diagnosis (Mycosis Fungoides and Sezary Syndrome) after one year Dupixent injections for adult-onset eczema.
Richardson v. Sanofi/Regeneron, filed Oct. 2025, M.D. Tenn. — Wrongful death action alleging Dupixent caused PTCL death of Cynthia Hyde. Case management conference held Dec. 8, 2025; response deadline Jan. 7, 2026 per Magistrate Judge Alistair Newbern order.
Cancer lawsuit filed Dec. 2025 per litigation tracking — standard 2-year product liability SOL applies; discovery rule likely available given CTCL latency period.
2-year SOL from discovery of injury; discovery rule critical given August 2024 AD study publication and March 2025 FDA serious risks listing.
3-year SOL under CPLR 214(2) for product liability; discovery rule and continuous treatment doctrine may toll claims.
2-year SOL under Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies.
Plaintiffs' proposed MDL venue — four cases already pending in N.D. Ga. JPML heard oral arguments May 28, 2026 on MDL 3180 centralization motion filed Feb. 13, 2026.
Key defendants
Sanofi-Aventis U.S. LLC
Role: Manufacturer
Named in all filed complaints; MDL motion filed Feb. 13, 2026 seeks consolidation of at least 15 federal cases. No answer or dismissal motion yet noted.
Regeneron Pharmaceuticals Inc.
Role: Manufacturer
Co-defendant with Sanofi; joint development and marketing of Dupixent. No separate defense posture reported; both defendants aligned in early litigation stage.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Sanofi-Aventis U.S. LLC | Manufacturer | Named in all filed complaints; MDL motion filed Feb. 13, 2026 seeks consolidation of at least 15 federal cases. No answer or dismissal motion yet noted. |
| Regeneron Pharmaceuticals Inc. | Manufacturer | Co-defendant with Sanofi; joint development and marketing of Dupixent. No separate defense posture reported; both defendants aligned in early litigation stage. |
Timeline
FDA Approves Dupixent for Atopic Dermatitis
FDA grants approval to Dupixent (dupilumab) for moderate-to-severe atopic dermatitis. Manufacturers: Sanofi and Regeneron.
Retrospective Study Links Dupixent to CTCL
Study published April 6, 2024 (Hasan et al.) finds Dupixent-treated atopic dermatitis patients had 4.1-fold increased odds of developing cutaneous T-cell lymphoma versus non-users. Most cases diagnosed more than one year post-initiation.
JAAD Publishes Full CTCL Study
Journal of the American Academy of Dermatology publishes complete retrospective cohort study confirming elevated CTCL risk in Dupixent users with atopic dermatitis.
FDA Adds Dupixent to Serious Risks List
FDA places Dupixent on quarterly 'Potential Signals of Serious Risks/New Safety Information' list due to reports of CTCL.
Wrongful Death Lawsuit Filed in Tennessee
Tennessee family files wrongful death lawsuit alleging fatal lymphoma from Dupixent use. Case: Richardson, M.D. Tenn., response deadline Jan. 7, 2026 per Magistrate Judge Alistair Newbern.
Federal Complaint Filed in Florida
Michael Durkin files complaint in U.S. District Court for the Middle District of Florida alleging Dupixent causes mycosis fungoides and Sézary syndrome, with failure-to-warn claims against Sanofi and Regeneron.
Plaintiffs File MDL Motion with JPML
Plaintiffs file motion for transfer with Judicial Panel on Multidistrict Litigation seeking consolidation of all federal Dupixent lymphoma cases. At least 15 cases pending across 12 district courts; four filed in Northern District of Georgia.
JPML Hears Oral Arguments on MDL Venue
JPML hears oral arguments in Milwaukee, Wisconsin. Both sides agree to centralization; plaintiffs propose N.D. Georgia, defendants seek S.D. New York. MDL No. 3180: In re: Dupixent (Dupilumab) Products Liability Litigation.
MDL 3180 Pending JPML Ruling
JPML ruling on MDL 3180 centralization and venue expected. No presiding judge assigned; no bellwether trials scheduled; no settlements reported. 26 cases pending per JPML data as of July 6, 2026.
Statute of limitations
No MDL established as of March 2026. Individual cases filed in federal courts including M.D. Tenn. (Richardson, response deadline Jan. 7, 2026 per Magistrate Judge Alistair Newbern). Primary accrual theories: (1) date of CTCL diagnosis; (2) date of discovery of Dupixent-CTCL link. FDA placed Dupixent on potential serious risks list March 2025; label still lacks CTCL warning per November 2025 reports. Discovery rule critical in most jurisdictions given latency period (August 2024 JAAD study showed 4.1x increased risk, median diagnosis >1 year post-initiation). Federal preemption defenses likely; no federal recall. Screen for: minimum 1 month Dupixent use; CTCL, mycosis fungoides, or Sézary syndrome diagnosis; no prior lymphoma/leukemia.
Delaware
2 years from date of injury or diagnosis
Rule: Product liability and personal injury claims must be filed within two years of the date of injury or diagnosis per Morris James LLP guidance
Discovery: Accrual may begin when symptoms first appeared, when diagnosis was made, or when connection to Dupixent was discovered
Exceptions may apply; early consultation advised given multiple potential accrual triggers
Tennessee
1 year from accrual (typical wrongful death)
Rule: Wrongful death claim filed October 2025 in M.D. Tenn. (Richardson v. Regeneron/Sanofi) with response deadline January 7, 2026 per Magistrate Judge Alistair Newbern order
Discovery: Accrual tied to death date or discovery of causation; case management conference held December 8, 2025
Federal court handling early bellwether; no MDL yet established
Illinois
2 years from accrual (typical personal injury)
Rule: Cancer lawsuit filed December 2025 per Sokolove Law update; standard Illinois product liability SOL applies
Discovery: Discovery rule likely available given CTCL latency period (studies show median diagnosis >1 year post-initiation)
Filed as individual action; no consolidation yet
California
2 years from discovery of injury
Rule: Discovery rule standard; accrual when plaintiff knew or should have known of injury and its cause
Discovery: Critical given August 2024 JAAD study publication and March 2025 FDA serious risks list placement as potential notice triggers
No state revival statute applicable; federal preemption defenses expected
New York
3 years from accrual
Rule: CPLR 214(2) product liability; 3 years from date of injury or discovery
Discovery: Discovery rule applies; continuous treatment doctrine may toll if misdiagnosis ongoing
Large plaintiff pool expected given Dupixent prescribing volume; screen for eczema patients with delayed CTCL diagnosis
Texas
2 years from accrual
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; product liability claims subject to 2-year SOL
Discovery: Discovery rule applies; fraudulent concealment possible given lack of CTCL warning on label
No pending revival legislation; federal court filings likely given manufacturer diversity
Florida
4 years from accrual (2 years wrongful death)
Rule: Fla. Stat. § 95.11(3)(a) product liability; 4 years for personal injury, 2 years for wrongful death
Discovery: Discovery rule applies; statute begins when injury discovered or should have been discovered with due diligence
Longer SOL window but early filing strategic given potential MDL formation
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Delaware | 2 years from date of injury or diagnosis | Product liability and personal injury claims must be filed within two years of the date of injury or diagnosis per Morris James LLP guidance | Accrual may begin when symptoms first appeared, when diagnosis was made, or when connection to Dupixent was discovered | Exceptions may apply; early consultation advised given multiple potential accrual triggers |
| Tennessee | 1 year from accrual (typical wrongful death) | Wrongful death claim filed October 2025 in M.D. Tenn. (Richardson v. Regeneron/Sanofi) with response deadline January 7, 2026 per Magistrate Judge Alistair Newbern order | Accrual tied to death date or discovery of causation; case management conference held December 8, 2025 | Federal court handling early bellwether; no MDL yet established |
| Illinois | 2 years from accrual (typical personal injury) | Cancer lawsuit filed December 2025 per Sokolove Law update; standard Illinois product liability SOL applies | Discovery rule likely available given CTCL latency period (studies show median diagnosis >1 year post-initiation) | Filed as individual action; no consolidation yet |
| California | 2 years from discovery of injury | Discovery rule standard; accrual when plaintiff knew or should have known of injury and its cause | Critical given August 2024 JAAD study publication and March 2025 FDA serious risks list placement as potential notice triggers | No state revival statute applicable; federal preemption defenses expected |
| New York | 3 years from accrual | CPLR 214(2) product liability; 3 years from date of injury or discovery | Discovery rule applies; continuous treatment doctrine may toll if misdiagnosis ongoing | Large plaintiff pool expected given Dupixent prescribing volume; screen for eczema patients with delayed CTCL diagnosis |
| Texas | 2 years from accrual | Tex. Civ. Prac. & Rem. Code § 16.003; product liability claims subject to 2-year SOL | Discovery rule applies; fraudulent concealment possible given lack of CTCL warning on label | No pending revival legislation; federal court filings likely given manufacturer diversity |
| Florida | 4 years from accrual (2 years wrongful death) | Fla. Stat. § 95.11(3)(a) product liability; 4 years for personal injury, 2 years for wrongful death | Discovery rule applies; statute begins when injury discovered or should have been discovered with due diligence | Longer SOL window but early filing strategic given potential MDL formation |
Live intelligence
AI litigation brief
Dupixent CTCL remains early-stage / recently consolidated with 45 current signals in the accepted feed.
Overview
JPML centralized federal Dupixent CTCL cases into MDL No. 3180 in the District of New Jersey on June 4, 2026, assigning Judge Zahid N. Quraishi to preside. The MDL currently holds 26 pending actions; litigation remains in early organizational stage with no bellwether trials scheduled.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3180, pointing to sustained litigation pressure rather than a one-off headline cycle. 5 live sources are contributing current context.
Editorial intelligence
MDL 3180 should stay on the lead docket watch because it is the primary consolidation vehicle for Dupixent CTCL.
Generated Aug 12, 2026, 3:00 AM UTC
45 events detected
Google News (10)
Cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with dupilumab or tralokinumab - Springer Nature Link
Dupixent and Cutaneous T-Cell Lymphoma: What Patients Should Know About the Growing Litigation - JD Supra
Sanofi tests Dupixent SC with Alteogen tech, expands beyond oncology - CHOSUNBIZ - Chosunbiz
Manufacturers of Dupixent Facing Lawsuits Over Drug Outcomes - GLK Law
Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court - Law360
Regeneron Opens Lower After Cancer Trial Setback - TechStock²
Regeneron Pharmaceuticals stock (US75811P1003): Biotech leader in eye and oncology treatments - ad-hoc-news.de
Regeneron Pharmaceuticals stock (US75811P1003): Biotech leader in eye and oncology treatments - AD HOC NEWS
Regeneron beats quarterly estimates on strong Dupixent demand - ETPharma.com
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings - BioSpace
Allergy • Ahn J • PMID 42560135 • Journal Article.
Journal of the European Academy of Dermatology and Venereology : JEADV • Mannava KA • PMID 42535520 • Editorial.
Chest • Lai CC • PMID 42521147 • Journal Article.
The European respiratory journal • Katial RK • PMID 42425748 • Letter.
The clinical respiratory journal • Yu Y • PMID 42423614 • Journal Article.
JPML Transfer Order — Centralized in D.N.J. before Judge Zahid N. Quraishi
The Panel grants transfer of Dupliumab products liability actions to a single district for coordinated pretrial proceedings, with the Northern District of Georgia as the likely transferee court.
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
88Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Aug 12, 2026, 3:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
45
events detected
AI Brief
Dupixent CTCL remains early-stage / recently consolidated with 45 current signals in the accepted feed.
Overview
JPML centralized federal Dupixent CTCL cases into MDL No. 3180 in the District of New Jersey on June 4, 2026, assigning Judge Zahid N. Quraishi to preside. The MDL currently holds 26 pending actions; litigation remains in early organizational stage with no bellwether trials scheduled.
Key developments
Case Management Orders court filing on Jun 4: JPML Transfer Order — Centralized in D.N.J. before Judge Zahid N. Quraishi. ‖ Springer Nature Link news on Jul 10: Cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with dupilumab or tralokinumab - Springer Nature Link. ‖ FAERS FDA alert on Jun 29: FAERS Filing 26936320: Lymphoma. ‖ PubMed research on Aug 6: Mycosis Fungoides-Like Atopic Dermatitis Represents a Th22-Dominant Inflammatory Endotype..
Generated Aug 12, 2026, 3:00 AM UTC
Tracked MDLs
← Previous
Nevro Spinal Cord Stimulators
Tracks pending JPML consolidation proceedings alleging Nevro HFX, Senza, and Omnia spinal cord stimulator systems caused neurological injury, device malfunction, and failed pain relief.
Next →
Spinal Cord Stimulators
Tracks litigation against Boston Scientific alleging SCS devices cause lead migration, nerve damage, and paralysis. Centralized in MDL 3181 (C.D. Cal.) by JPML transfer order.